Short Interest in Global X HealthTech ETF (NASDAQ:HEAL) Grows By 67.9%

Global X HealthTech ETF (NASDAQ:HEAL) saw a significant increase in short interest in July. As of July 15th, there was short interest totaling 22,725 shares, an increase of 67.9% from the June 30th total of 13,534 shares. Approximately 2.1% of the company’s shares are short sold. Based on an average daily volume of 7,171 shares, the days-to-cover ratio is presently 3.2 days.

Global X HealthTech ETF Stock Down 1.0%

HEAL opened at $26.89 on Friday. Global X HealthTech ETF has a 12 month low of $23.00 and a 12 month high of $33.59. The company has a fifty day simple moving average of $26.72 and a 200 day simple moving average of $26.33. The stock has a market cap of $28.50 million, a P/E ratio of 42.80 and a beta of 1.10.

Hedge Funds Weigh In On Global X HealthTech ETF

Large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada grew its holdings in shares of Global X HealthTech ETF by 39.4% in the 1st quarter. Royal Bank of Canada now owns 2,603 shares of the company’s stock valued at $62,000 after acquiring an additional 736 shares in the last quarter. WT Wealth Management raised its holdings in Global X HealthTech ETF by 14.7% during the first quarter. WT Wealth Management now owns 101,116 shares of the company’s stock worth $2,409,000 after acquiring an additional 12,945 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Global X HealthTech ETF by 26,522.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,396 shares of the company’s stock valued at $70,000 after purchasing an additional 2,387 shares during the last quarter. Farther Finance Advisors LLC acquired a new position in Global X HealthTech ETF during the fourth quarter valued at approximately $111,000. Finally, Flow Traders U.S. LLC bought a new position in Global X HealthTech ETF in the third quarter valued at approximately $368,000.

Global X HealthTech ETF Company Profile

An ETF that invests in companies at the intersection of healthcare and technology, targeting innovations in drug discovery, medical devices, consumer healthcare, and analytics.